Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

HIMS has 210.1 million shares outstanding, but 58.2 million, or 30.4% of the total, are sold short. Many investors don’t like short-sellers because they look for stocks to fail. Yet, it’s all ...

RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operations ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Apostrophe, a skin care telehealth brand headquartered in the Bay Area, is shutting down after almost four years under the Hims & Hers corporate umbrella. The skin care company, founded in ...

Hims & Hers is shutting down the dermatology business it acquired four years ago, Business Insider has learned. On Friday, the telehealth company discontinued Apostrophe, the direct-to-consumer ...

Hims & Hers Health reported Q4 revenue of $481.14M, beating estimates of $470.31M, with EPS of $0.11, in line with expectations. The company’s Q4 revenue grew 69% YoY, with subscribers rising 45 ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims ...